Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease. ...